{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T04:07:25Z","timestamp":1750824445566,"version":"3.41.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,24]]},"DOI":"10.7759\/cureus.86645","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T09:51:16Z","timestamp":1750758676000},"source":"Crossref","is-referenced-by-count":0,"title":["Identified Medications Causing Medication-Related Osteonecrosis of the Jaw: A Literature Review"],"prefix":"10.7759","author":[{"given":"Nasimeh","family":"Baghalipour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omid","family":"Moztarzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Micopulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walla","family":"Samara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Hauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2022.02.008","article-title":"American Association of Oral and Maxillofacial Surgeons' position paper on medication-related osteonecrosis of the jaws\u20142022 update","volume":"80","author":"Ruggiero SL","year":"2022","unstructured":"Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons' position paper on medication-related osteonecrosis of the jaws\u20142022 update. J Oral Maxillofac Surg. 2022, 80:920-43. 10.1016\/j.joms.2022.02.008","journal-title":"J Oral Maxillofac Surg"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.21037\/fomm-21-106","article-title":"Medication-related osteonecrosis of the jaw: a narrative review of risk factors, diagnosis, and management","volume":"5","author":"Thomas JG","year":"2023","unstructured":"Thomas JG, Ouanounou A. Medication-related osteonecrosis of the jaw: a narrative review of risk factors, diagnosis, and management. Front Oral Maxillofac Med. 2023, 5:31. 10.21037\/fomm-21-106","journal-title":"Front Oral Maxillofac Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-024-01912-6","article-title":"How we manage medication-related osteonecrosis of the jaw","volume":"29","author":"Byrne H","year":"2024","unstructured":"Byrne H, O'Reilly S, Weadick CS, Brady P, R\u00edord\u00e1in RN. How we manage medication-related osteonecrosis of the jaw. Eur J Med Res. 2024, 29:402. 10.1186\/s40001-024-01912-6","journal-title":"Eur J Med Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14681","article-title":"Medication-related osteonecrosis of the jaw: analysing the range of implicated drugs from the Australian database of adverse event notifications","volume":"87","author":"Teoh L","year":"2021","unstructured":"Teoh L, Moses G, Nguyen AP, McCullough MJ. Medication-related osteonecrosis of the jaw: analysing the range of implicated drugs from the Australian database of adverse event notifications. Br J Clin Pharmacol. 2021, 87:2767-76. 10.1111\/bcp.14681","journal-title":"Br J Clin Pharmacol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s40729-021-00323-0","article-title":"Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review","volume":"7","author":"Kawahara M","year":"2021","unstructured":"Kawahara M, Kuroshima S, Sawase T. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review. Int J Implant Dent. 2021, 7:47. 10.1186\/s40729-021-00323-0","journal-title":"Int J Implant Dent"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s40902-023-00377-7","article-title":"Associated systemic diseases and etiologies of medication-related osteonecrosis of the jaw: a retrospective study of 265 surgical cases","volume":"45","author":"Chang HJ","year":"2023","unstructured":"Chang HJ, Kim MJ, Ahn KM. Associated systemic diseases and etiologies of medication-related osteonecrosis of the jaw: a retrospective study of 265 surgical cases. Maxillofac Plast Reconstr Surg. 2023, 45:12. 10.1186\/s40902-023-00377-7","journal-title":"Maxillofac Plast Reconstr Surg"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.archoralbio.2023.105792","article-title":"Bisphosphonates and osteonecrosis of the jaws: clinical and forensic aspects","volume":"155","author":"Nogueira D","year":"2023","unstructured":"Nogueira D, Caldas IM, Dinis-Oliveira RJ. Bisphosphonates and osteonecrosis of the jaws: clinical and forensic aspects. Arch Oral Biol. 2023, 155:105792. 10.1016\/j.archoralbio.2023.105792","journal-title":"Arch Oral Biol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare12040457","article-title":"Could MRONJ be related to osimertinib monotherapy in lung cancer patients after denosumab suspension?","volume":"12","author":"Forte M","year":"2024","unstructured":"Forte M, d'Amati A, Limongelli L, et al.. Could MRONJ be related to osimertinib monotherapy in lung cancer patients after denosumab suspension?. Healthcare (Basel. 2024, 12:457. 10.3390\/healthcare12040457","journal-title":"Healthcare (Basel"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.14476\/jomp.2022.47.1.1","article-title":"Medication-related osteonecrosis of the jaws: a literature review","volume":"47","author":"Kim GM","year":"2022","unstructured":"Kim GM, Moon SY, You JS, et al.. Medication-related osteonecrosis of the jaws: a literature review. J Oral Med Pain. 2022, 47:1-9. 10.14476\/jomp.2022.47.1.1","journal-title":"J Oral Med Pain"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/2684924","article-title":"The dental management of patients at risk of medication-related osteonecrosis of the jaw: new paradigm of primary prevention","volume":"2018","author":"Di Fede O","year":"2018","unstructured":"Di Fede O, Panzarella V, Mauceri R, et al.. The dental management of patients at risk of medication-related osteonecrosis of the jaw: new paradigm of primary prevention. Biomed Res Int. 2018, 2018:2684924. 10.1155\/2018\/2684924","journal-title":"Biomed Res Int"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/diseases12090205","article-title":"Medication-related osteonecrosis of the jaw: a systematic review of case reports and case series","volume":"12","author":"Frutuoso F","year":"2024","unstructured":"Frutuoso F, Freitas F, Vilares M, Francisco H, Marques D, Caram\u00eas J, Moreira A. Medication-related osteonecrosis of the jaw: a systematic review of case reports and case series. Diseases. 2024, 12:205. 10.3390\/diseases12090205","journal-title":"Diseases"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-018-4501-x","article-title":"Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review","volume":"27","author":"Nicolatou-Galitis O","year":"2019","unstructured":"Nicolatou-Galitis O, Kouri M, Papadopoulou E, et al.. Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review. Support Care Cancer. 2019, 27:383-94. 10.1007\/s00520-018-4501-x","journal-title":"Support Care Cancer"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.53394\/akd.1211550","article-title":"MRONJ with current diagnostic and treatment approaches","volume":"10","author":"\u00d6\u00e7al M\u00c7","year":"2024","unstructured":"\u00d6\u00e7al M\u00c7, Co\u015fgun Baybars S, Duran MH. MRONJ with current diagnostic and treatment approaches. Akdeniz T\u0131p Dergisi. 2024, 10:188-98. 10.53394\/akd.1211550","journal-title":"Akdeniz T\u0131p Dergisi"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/8071579","article-title":"Osteonecrosis of the jaw associated with antiangiogenics in antiresorptivena\u00efve patient: a comprehensive review of the literature","volume":"2018","author":"Pimolbutr K","year":"2018","unstructured":"Pimolbutr K, Porter S, Fedele S. Osteonecrosis of the jaw associated with antiangiogenics in antiresorptivena\u00efve patient: a comprehensive review of the literature. Biomed Res Int. 2018, 2018:8071579. 10.1155\/2018\/8071579","journal-title":"Biomed Res Int"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjoms.2021.03.006","article-title":"Systematic review of medication related osteonecrosis of the jaw (MRONJ) in patients undergoing only antiangiogenic drug therapy: surgery or conservative therapy?","volume":"60","author":"Sacco R","year":"2022","unstructured":"Sacco R, Woolley J, Patel G, Calasans-Maia MD, Yates J. Systematic review of medication related osteonecrosis of the jaw (MRONJ) in patients undergoing only antiangiogenic drug therapy: surgery or conservative therapy?. Br J Oral Maxillofac Surg. 2022, 60:216-30. 10.1016\/j.bjoms.2021.03.006","journal-title":"Br J Oral Maxillofac Surg"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/odi.15198","article-title":"Mechanisms underlying medication-related osteonecrosis of the jaw","volume":"31","author":"Lee K","year":"2025","unstructured":"Lee K, Kim K, Kim JY, Kim JW, Kang YH, Kim YH, Kim SJ. Mechanisms underlying medication-related osteonecrosis of the jaw. Oral Dis. 2025, 31:1073-83. 10.1111\/odi.15198","journal-title":"Oral Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jormas.2023.101645","article-title":"Risk of healing impairment following tooth extraction in patients administered with antiresorptive and non-antiresorptive polypharmacy","volume":"125","author":"Suryani IR","year":"2024","unstructured":"Suryani IR, Shujaat S, Ivkovi\u0107 U, Coucke W, Coropciuc R, Jacobs R. Risk of healing impairment following tooth extraction in patients administered with antiresorptive and non-antiresorptive polypharmacy. J Stomatol Oral Maxillofac Surg. 2024, 125:101645. 10.1016\/j.jormas.2023.101645","journal-title":"J Stomatol Oral Maxillofac Surg"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10204762","article-title":"Cancer patients at risk for medication-related osteonecrosis of the jaw. A case and control study analyzing predictors of MRONJ onset","volume":"10","author":"Marcian\u00f2 A","year":"2021","unstructured":"Marcian\u00f2 A, Ingrasciotta Y, Isgr\u00f2 V, et al.. Cancer patients at risk for medication-related osteonecrosis of the jaw. A case and control study analyzing predictors of MRONJ onset. J Clin Med. 2021, 10:4762-10. 10.3390\/jcm10204762","journal-title":"J Clin Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.sdentj.2023.07.006","article-title":"Correlation of anti-TNF-a biological therapy with periodontal conditions and osteonecrosis in autoimmune patients: a systematic review","volume":"35","author":"Majdi Abunemer R","year":"2023","unstructured":"Majdi Abunemer R, Saifuddin Shaheen R, Abudullah Alghamdi R. Correlation of anti-TNF-a biological therapy with periodontal conditions and osteonecrosis in autoimmune patients: a systematic review. SaudiDent J. 2023, 35:785-96. 10.1016\/j.sdentj.2023.07.006","journal-title":"SaudiDent J"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.18905\/jodu.58.1_153","article-title":"Risk assessment of medication-related osteonecrosis of the jaw by alveolar bone mineral density","volume":"58","author":"Hamada S","year":"2024","unstructured":"Hamada S, Watanabe M, Nakajima M, et al.. Risk assessment of medication-related osteonecrosis of the jaw by alveolar bone mineral density. J Osaka Dent Univ. 2024, 58:153-64. 10.18905\/jodu.58.1_153","journal-title":"J Osaka Dent Univ"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S490982","article-title":"Secukinumab causing medication-related osteonecrosis of the jaw, in a patient diagnosed with psoriasis and rheumatoid arthritis","volume":"14","author":"Hauer L","year":"2024","unstructured":"Hauer L, Moztarzadeh O, Baghalipour N, Gencur J. Secukinumab causing medication-related osteonecrosis of the jaw, in a patient diagnosed with psoriasis and rheumatoid arthritis. Psoriasis (Auckl. 2024, 14:115-20. 10.2147\/PTT.S490982","journal-title":"Psoriasis (Auckl"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jormas.2024.101985","article-title":"Guselkumab: a new etiological factor of medication related osteonecrosis of the jaw (MRONJ)? A case report","volume":"125","author":"Marotta M","year":"2024","unstructured":"Marotta M, Boffano P, Prota E, Ferrillo M, Leone S, Fusco V, Migliario M. Guselkumab: a new etiological factor of medication related osteonecrosis of the jaw (MRONJ)? A case report. J Stomatol Oral MaxillofacSurg. 2024, 125:101985. 10.1016\/j.jormas.2024.101985","journal-title":"J Stomatol Oral MaxillofacSurg"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3205\/iprs000153","article-title":"Tocilizumab: another medication related to osteonecrosis of the jaws? A case report and literature review","volume":"10","author":"Sakkas A","year":"2021","unstructured":"Sakkas A, Heil S, Kargus S, Rebel M, Mischkowski RA, Thiele OC. Tocilizumab: another medication related to osteonecrosis of the jaws? A case report and literature review. GMS Interdiscip Plast Reconstr Surg DGPW. 2021, 10:03. 10.3205\/iprs000153","journal-title":"GMS Interdiscip Plast Reconstr Surg DGPW"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/s40729-019-0188-0","article-title":"A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants","volume":"5","author":"Maluf G","year":"2019","unstructured":"Maluf G, Caldas RJ, Fregnani ER, da Silva Santos PS. A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants. Int J Implant Dent. 2019, 5:34. 10.1186\/s40729-019-0188-0","journal-title":"Int J Implant Dent"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2016.05.07","article-title":"","volume":"7","author":"Mawardi H","year":"2016","unstructured":"Mawardi H, Enzinger P, McCleary N, Manon R, Villa A, Treister N, Woo SB. Osteonecrosis of the jaw associated with ziv-aflibercept. J Gastrointest Oncol. 2016, 7:81-7. 10.21037\/jgo.2016.05.07","journal-title":"Osteonecrosis of the jaw associated with ziv-aflibercept. J Gastrointest Oncol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1307860","article-title":"Recent advances of anti-angiogenic inhibitors targeting VEGF\/VEGFR axis","volume":"14","author":"Wang L","year":"2023","unstructured":"Wang L, Liu WQ, Broussy S, Han B, Fang H. Recent advances of anti-angiogenic inhibitors targeting VEGF\/VEGFR axis. Front Pharmacol. 2023, 14:1307860. 10.3389\/fphar.2023.1307860","journal-title":"Front Pharmacol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3389\/froh.2024.1427060","article-title":"Case report: development of medication-related osteonecrosis of the jaw in a patient on long-term infliximab therapy","volume":"5","author":"Oryniak D","year":"2024","unstructured":"Oryniak D, Brown M, Cholakis L, Elgazzar R. Case report: development of medication-related osteonecrosis of the jaw in a patient on long-term infliximab therapy. Front Oral Health. 2024, 5:1427060. 10.3389\/froh.2024.1427060","journal-title":"Front Oral Health"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/5544285","article-title":"Medication-related osteonecrosis of the jaw: a case report of an unusual side effect of adalimumab","volume":"2023","author":"Sisalli L","unstructured":"Sisalli L, Giordano F, Chiacchio A, Acerra A, Caggiano M. Medication-related osteonecrosis of the jaw: a case report of an unusual side effect of adalimumab. Case Rep Dent. 2023:5544285. 10.1155\/2023\/5544285","journal-title":"Case Rep Dent"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.947947","article-title":"Osimertinib: another medication related to osteonecrosis of the jaws? A case report and literature review","volume":"13","author":"Wang F","year":"2022","unstructured":"Wang F, Wei S, Zhang Z, Zhang Y, He J, Sun B. Osimertinib: another medication related to osteonecrosis of the jaws? A case report and literature review. Front Pharmacol. 2022, 13:947947. 10.3389\/fphar.2022.947947","journal-title":"Front Pharmacol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6621937","article-title":"Medicationrelated osteonecrosis of the jaw spontaneously occurred in a patient with chronic myelogenous leukemia only by imatinib: a report of a rare case","volume":"2021","author":"Okubo-Sato M","unstructured":"Okubo-Sato M, Yamagata K, Fukuzawa S, Terada K, Uchida F, Ishibashi-Kanno N, Bukawa H. Medicationrelated osteonecrosis of the jaw spontaneously occurred in a patient with chronic myelogenous leukemia only by imatinib: a report of a rare case. Case Rep Dent. 2021:6621937. 10.1155\/2021\/6621937","journal-title":"Case Rep Dent"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/adj.12723","article-title":"Osteonecrosis of the jaw in an anti-resorptive na\u00efve patient taking trastuzumab and pertuzumab: case report","volume":"65","author":"Manzie T","year":"2020","unstructured":"Manzie T, Vujcich N, Chan A. Osteonecrosis of the jaw in an anti-resorptive na\u00efve patient taking trastuzumab and pertuzumab: case report. Aust Dent J. 2020, 65:305-7. 10.1111\/adj.12723","journal-title":"Aust Dent J"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14010094","article-title":"Rituximab as a trigger factor of medication-related osteonecrosis of the jaw. A case report","volume":"121","author":"Javelot MJ","year":"2020","unstructured":"Javelot MJ, Sergheraert J, Agbo-Godeau S, et al.. Rituximab as a trigger factor of medication-related osteonecrosis of the jaw. A case report. J Stomatol Oral Maxillofac Surg. 2020, 121:300-4. 10.3390\/cancers14010094","journal-title":"J Stomatol Oral Maxillofac Surg"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-023-00657-y","article-title":"Medication-induced osteonecrosis of the jaw: a review of cases from the Food and Drug Administration Adverse Event Reporting System (FAERS)","volume":"24","author":"Ahdi HS","year":"2023","unstructured":"Ahdi HS, Wichelmann TA, Pandravada S, Ehrenpreis ED. Medication-induced osteonecrosis of the jaw: a review of cases from the Food and Drug Administration Adverse Event Reporting System (FAERS). BMC Pharmacol Toxicol. 2023, 24:15. 10.1186\/s40360-023-00657-y","journal-title":"BMC Pharmacol Toxicol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.3418","article-title":"New-generation anticancer drugs and medicationrelated osteonecrosis of the jaw (MRONJ): late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy","volume":"9","author":"Guida A","year":"2021","unstructured":"Guida A, Perri F, Ionna F, Ascierto PA, Grimaldi AM. New-generation anticancer drugs and medicationrelated osteonecrosis of the jaw (MRONJ): late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy. Clin Case Rep. 2021, 9:61-6. 10.1002\/ccr3.3418","journal-title":"Clin Case Rep"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.23937\/2469-5734\/1510033","article-title":"Medication-related osteonecrosis of the jaw with the mTOR inhibitor everolimus in a patient with estrogen-receptor positive breast cancer: a case report","volume":"2","author":"Lee CY","year":"2016","unstructured":"Lee CY, Lee KL, Hirata KY, Suzuki JB. Medication-related osteonecrosis of the jaw with the mTOR inhibitor everolimus in a patient with estrogen-receptor positive breast cancer: a case report. Int J Oral Dent Health. 2016, 2:33. 10.23937\/2469-5734\/1510033","journal-title":"Int J Oral Dent Health"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.20517\/2394-4722.2016.06","article-title":"Osteonecrosis of the jaw in a patient with acute myeloid leukemia, who received azacitidine","volume":"2","author":"Nicolatou-Galitis O","year":"2016","unstructured":"Nicolatou-Galitis O, Galiti D, Moschogianni M, et al.. Osteonecrosis of the jaw in a patient with acute myeloid leukemia, who received azacitidine. J Cancer Metastasis Treat. 2016, 2:220-3. 10.20517\/2394-4722.2016.06","journal-title":"J Cancer Metastasis Treat"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.oooo.2017.09.005","article-title":"Methotrexate-associated osteonecrosis of the jaw: a report of two cases","volume":"124","author":"Henien M","year":"2017","unstructured":"Henien M, Carey B, Hullah E, Sproat C, Patel V. Methotrexate-associated osteonecrosis of the jaw: a report of two cases. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017, 124:283-7. 10.1016\/j.oooo.2017.09.005","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1007\/s10006-020-00851-w","article-title":"Necrotizing periodontitis or medication-related osteonecrosis of the jaw (MRONJ) in a patient receiving Bemcentinib\u2014a case report","volume":"24","author":"Bumm CV","year":"2020","unstructured":"Bumm CV, Folwaczny M, W\u00f6lfle UC. Necrotizing periodontitis or medication-related osteonecrosis of the jaw (MRONJ) in a patient receiving Bemcentinib\u2014a case report. Oral Maxillofac Surg. 2020, 24:353-8. 10.1007\/s10006-020-00851-w","journal-title":"Oral Maxillofac Surg"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3390\/dj11040104","article-title":"Multiple-drugs-related osteonecrosis of the jaw in a patient affected by multiple myeloma: a case report","volume":"11","author":"Caggiano M","year":"2023","unstructured":"Caggiano M, Di Spirito F, Acerra A, Galdi M, Sisalli L. Multiple-drugs-related osteonecrosis of the jaw in a patient affected by multiple myeloma: a case report. Dent J (Basel. 2023, 11:104. 10.3390\/dj11040104","journal-title":"Dent J (Basel"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200202283460902","article-title":"","volume":"346","author":"Solomon CG: Bisphosphonates and osteoporosis","year":"2002","unstructured":"Solomon CG. Bisphosphonates and osteoporosis: N Engl J Med. 2002, 346:642. 10.1056\/NEJM200202283460902","journal-title":"N Engl J Med"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01936-y","article-title":"Denosumab in the treatment of osteoporosis: 10 years later: a narrative review","volume":"39","author":"Kendler DL","year":"2022","unstructured":"Kendler DL, Cosman F, Stad RK, Ferrari S. Denosumab in the treatment of osteoporosis: 10 years later: a narrative review. Adv Ther. 2022, 39:58-74. 10.1007\/s12325-021-01936-y","journal-title":"Adv Ther"},{"key":"ref43","doi-asserted-by":"crossref","DOI":"10.31744\/einstein_journal\/2019RW4628","article-title":"Risk profile for antiangiogenic agent-related osteonecrosis of the jaws","volume":"17","author":"Caminha RD","year":"2019","unstructured":"Caminha RD, Chicrala GM, Soares J\u00fanior LA, Santos PS. Risk profile for antiangiogenic agent-related osteonecrosis of the jaws. Einstein (Sao Paulo. 2019, 17:4628.","journal-title":"Einstein (Sao Paulo"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713317","article-title":"Vascular endothelial growth factor-d (VEGF-D): an angiogenesis bypass in malignant tumors","volume":"24","author":"Bokhari SM","year":"2023","unstructured":"Bokhari SM, Hamar P. Vascular endothelial growth factor-d (VEGF-D): an angiogenesis bypass in malignant tumors. Int J Mol Sci. 2023, 24:13317. 10.3390\/ijms241713317","journal-title":"Int J Mol Sci"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijom.2020.05.017","article-title":"Medication-related osteonecrosis of the jaws associated with intravitreal administration of ranibizumab","volume":"49","author":"Oz I","year":"2020","unstructured":"Oz I, Kaplan I, Kleinman S, Arbel S, Shuster A. Medication-related osteonecrosis of the jaws associated with intravitreal administration of ranibizumab. Int J Oral Maxillofac Surg. 2020, 49:1589-91. 10.1016\/j.ijom.2020.05.017","journal-title":"Int J Oral Maxillofac Surg"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/852748","article-title":"Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications","volume":"2014","author":"Iqbal N","year":"2014","unstructured":"Iqbal N, Iqbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int. 2014, 2014:852748. 10.1155\/2014\/852748","journal-title":"Mol Biol Int"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.03.017","article-title":"","volume":"149","author":"Laplante M","year":"2012","unstructured":"Laplante M, Sabatini DM. mTOR signaling in growth control and disease: Cell. 2012, 149:274-93. 10.1016\/j.cell.2012.03.017","journal-title":"Cell"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2009.10.009","article-title":"Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations","volume":"36","author":"Boni JP","year":"2009","unstructured":"Boni JP, Hug B, Leister C, Sonnichsen D. Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations. Semin Oncol. 2009, 36:18-25. 10.1053\/j.seminoncol.2009.10.009","journal-title":"Semin Oncol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jormas.2022.03.012","article-title":"Possible association of methotrexate use with osteonecrosis of the jaw: systematic review","author":"Milosavljevi\u0107 M","year":"2022123","unstructured":"Milosavljevi\u0107 M, Jovanovi\u0107 M, Foli\u0107 M, \u017divi\u0107 M, Zdravkovi\u0107 D, Veli\u010dkovi\u0107 S, Jankovi\u0107 S. Possible association of methotrexate use with osteonecrosis of the jaw: systematic review. J Stomatol Oral Maxillofac Surg. 2022123, 458-63. 10.1016\/j.jormas.2022.03.012","journal-title":"J Stomatol Oral Maxillofac Surg"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.4317\/medoral.23191","article-title":"Review and update on drugs related to the development of osteonecrosis of the jaw","volume":"25","author":"Eguia A","year":"2020","unstructured":"Eguia A, Bag\u00e1n-Deb\u00f3n L, Cardona F. Review and update on drugs related to the development of osteonecrosis of the jaw. Med Oral Patol Oral Cir Bucal. 2020, 25:71-83. 10.4317\/medoral.23191","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1186\/s12903-024-05081-0","article-title":"Potential role of comprehensive dental care in preventing medication related osteonecrosis of the jaw (MRONJ): a single centre study","volume":"24","author":"Alblazi K","year":"2024","unstructured":"Alblazi K, Nabil S, Tumian NR, Yunus SS, Ramli R. Potential role of comprehensive dental care in preventing medication related osteonecrosis of the jaw (MRONJ): a single centre study. BMC Oral Health. 2024, 24:1291. 10.1186\/s12903-024-05081-0","journal-title":"BMC Oral Health"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20142014 update","volume":"72","author":"Ruggiero SL","year":"2014","unstructured":"Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O'Ryan F. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20142014 update. J Oral Maxillofac Surg. 2014, 72:1938-56. 10.1016\/j.joms.2014.04.031","journal-title":"J Oral Maxillofac Surg"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1111\/odi.14887","article-title":"Italian position paper (SIPMO-SICMF) on medication-related osteonecrosis of the jaw (MRONJ)","volume":"30","author":"Bedogni A","year":"2024","unstructured":"Bedogni A, Mauceri R, Fusco V, et al.. Italian position paper (SIPMO-SICMF) on medication-related osteonecrosis of the jaw (MRONJ). Oral Dis. 2024, 30:3679-709. 10.1111\/odi.14887","journal-title":"Oral Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/373812-identified-medications-causing-medication-related-osteonecrosis-of-the-jaw-a-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T09:51:19Z","timestamp":1750758679000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/373812-identified-medications-causing-medication-related-osteonecrosis-of-the-jaw-a-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":53,"URL":"https:\/\/doi.org\/10.7759\/cureus.86645","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,24]]}}}